Crystal structure of rhizavidin: insights into the enigmatic high-affinity interaction of an innate biotin-binding protein dimer.

A. Meir,Satu H. Helppolainen,E. Podoly,H. Nordlund,V. Hytönen,J. Määttä,M. Wilchek,E. Bayer,M. Kulomaa,O. Livnah

DOI: https://doi.org/10.1016/j.jmb.2008.11.061

IF: 6.151

2009-02-20

Journal of Molecular Biology

Abstract:

What problem does this paper attempt to address?

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

Yichao Wu,Zhikun Liu,Xiao Xu

DOI: https://doi.org/10.1002/cac2.12115

IF: 15.2825

2020-01-01

Cancer Communications

Abstract:Hepatocellular carcinoma (HCC) is one of the most prevalent and fatal digestive tumors. Treatment for this disease has been constraint by heterogeneity of this group of tumors, which has greatly limited the progress in personalized therapy. Although existing studies have revealed the genetic and epigenetic blueprints that drive HCCs, many of the molecular mechanisms that lead to HCCs remain elusive. Recent advances in techniques for studying functional genomics, such as genome sequencing and transcriptomic analyses, have led to the discovery of molecular mechanisms that participate in the initiation and evolution of HCC. Integrative multi‐omics analyses have identified several molecular subtypes of HCC associated with specific molecular characteristics and clinical outcomes. Deciphering similar molecular features among highly heterogeneous HCC patients is a prerequisite to implementation of personalized therapeutics. This review summarizes the current research progresses in precision therapy on the backbone of molecular subtypes of HCC.
De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity

Seyed H Moosavi,Peter W Eide,Ina A Eilertsen,Tuva H Brunsell,Kaja C G Berg,Bård I Røsok,Kristoffer W Brudvik,Bjørn A Bjørnbeth,Marianne G Guren,Arild Nesbakken,Ragnhild A Lothe,Anita Sveen

DOI: https://doi.org/10.1186/s13073-021-00956-1

2021-09-01

Abstract:Background: Gene expression-based subtyping has the potential to form a new paradigm for stratified treatment of colorectal cancer. However, current frameworks are based on the transcriptomic profiles of primary tumors, and metastatic heterogeneity is a challenge. Here we aimed to develop a de novo metastasis-oriented framework. Methods: In total, 829 transcriptomic profiles from patients with colorectal cancer were analyzed, including primary tumors, liver metastases, and non-malignant liver samples. High-resolution microarray gene expression profiling was performed of 283 liver metastases from 171 patients treated by hepatic resection, including multiregional and/or multi-metastatic samples from each of 47 patients. A single randomly selected liver metastasis sample from each patient was used for unsupervised subtype discovery by nonnegative matrix factorization, and a random forest prediction model was trained to classify multi-metastatic samples, as well as liver metastases from two independent series of 308 additional patients. Results: Initial comparisons with non-malignant liver samples and primary colorectal tumors showed a highly variable degree of influence from the liver microenvironment in metastases, which contributed to inter-metastatic transcriptomic heterogeneity, but did not define subtype distinctions. The de novo liver metastasis subtype (LMS) framework recapitulated the main distinction between epithelial-like and mesenchymal-like tumors, with a strong immune and stromal component only in the latter. We also identified biologically distinct epithelial-like subtypes originating from different progenitor cell types. LMS1 metastases had several transcriptomic features of cancer aggressiveness, including secretory progenitor cell origin, oncogenic addictions, and microsatellite instability in a microsatellite stable background, as well as frequent RAS/TP53 co-mutations. The poor-prognostic association of LMS1 metastases was independent of mutation status, clinicopathological variables, and current subtyping frameworks (consensus molecular subtypes and colorectal cancer intrinsic subtypes). LMS1 was also the least heterogeneous subtype in comparisons of multiple metastases per patient, and tumor heterogeneity did not confound the prognostic value of LMS1. Conclusions: We report the first large study of multi-metastatic gene expression profiling of colorectal cancer. The new metastasis-oriented subtyping framework showed potential for clinically relevant transcriptomic classification in the context of metastatic heterogeneity, and an LMS1 mini-classifier was constructed to facilitate prognostic stratification and further clinical testing.
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics

Alberto Valdeolivas,Bettina Amberg,Nicolas Giroud,Marion Richardson,Eric J. C. Gálvez,Solveig Badillo,Alice Julien-Laferrière,Demeter Túrós,Lena Voith von Voithenberg,Isabelle Wells,Benedek Pesti,Amy A. Lo,Emilio Yángüez,Meghna Das Thakur,Michael Bscheider,Marc Sultan,Nadine Kumpesa,Björn Jacobsen,Tobias Bergauer,Julio Saez-Rodriguez,Sven Rottenberg,Petra C. Schwalie,Kerstin Hahn

DOI: https://doi.org/10.1038/s41698-023-00488-4

2024-01-10

npj Precision Oncology

Abstract:Abstract The consensus molecular subtypes (CMS) of colorectal cancer (CRC) is the most widely-used gene expression-based classification and has contributed to a better understanding of disease heterogeneity and prognosis. Nevertheless, CMS intratumoral heterogeneity restricts its clinical application, stressing the necessity of further characterizing the composition and architecture of CRC. Here, we used Spatial Transcriptomics (ST) in combination with single-cell RNA sequencing (scRNA-seq) to decipher the spatially resolved cellular and molecular composition of CRC. In addition to mapping the intratumoral heterogeneity of CMS and their microenvironment, we identified cell communication events in the tumor-stroma interface of CMS2 carcinomas. This includes tumor growth-inhibiting as well as -activating signals, such as the potential regulation of the ETV4 transcriptional activity by DCN or the PLAU-PLAUR ligand-receptor interaction. Our study illustrates the potential of ST to resolve CRC molecular heterogeneity and thereby help advance personalized therapy.

oncology
The Combination of Exon Sequencing and Metabolomics to Establish a Molecular Typing System for Gastric Cancer

Shanshan Yu,Ming Chen,Xiaohua Zhu,Cheng Chen,Jinxiao Liang,Haiyong Wang,Jun Lu,Yongfeng Ding,Mei Kong,Lisong Teng,Donghui Zhou

DOI: https://doi.org/10.1016/j.heliyon.2024.e34317

IF: 3.776

2024-01-01

Heliyon

Abstract:Background Gastric cancer (GC) is one of the most common malignant tumors in the world. It has become increasingly difficult to meet the needs of precision therapy using the existing molecular typing system. Therefore, developing a more effective molecular typing system for GC is urgent. Methods In this study, 100 Chinese GC patients were included. Whole-exome sequencing (WES) and metabolomics analysis were performed to reveal the characteristics of genomic and metabolic changes. Results In WES, nonsynonymous mutations accounted for the majority. Based on metabolomics, GC has been divided into three subtypes with distinct metabolic features. Importantly, we ultimately divided GC into four subtypes with different metabolic characteristics, genomic alterations, and clinical prognoses by incorporating biomics analysis. Conclusions Integrating biological features, we constructed a novel molecular system for GC that was closely related to genetics and metabolism, providing new insights for further understanding the heterogeneity and formulating precise treatment strategies.
Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

Qin Dang,Lulu Zuo,Xinru Hu,Zhaokai Zhou,Shuang Chen,Shutong Liu,Yuhao Ba,Anning Zuo,Hui Xu,Siyuan Weng,Yuyuan Zhang,Peng Luo,Quan Cheng,Zaoqu Liu,Xinwei Han

DOI: https://doi.org/10.1002/cam4.70041

IF: 4.711

2024-07-27

Cancer Medicine

Abstract:Background Colorectal cancer (CRC) is among the most hackneyed malignancies. Even patients with identical clinical symptoms and the same TNM stage still exhibit radically different clinical outcomes after receiving equivalent treatment regimens, indicating extensive heterogeneity of CRC. Myriad molecular subtypes of CRC have been exploited for decades, including the most compelling consensus molecular subtype (CMS) classification that has been broadly applied for patient stratification and biomarker‐drug combination formulation. Encountering barriers to clinical translation, however, CMS classification fails to fully reflect inter‐ or intra‐tumor heterogeneity of CRC. As a consequence, addressing heterogeneity and precisely managing CRC patients with unique characteristics remain arduous tasks for clinicians. Review In this review, we systematically summarize molecular subtypes of CRC and further elaborate on their clinical applications, limitations, and future orientations. Conclusion In recent years, exploration of subtypes through cell lines, animal models, patient‐derived xenografts (PDXs), organoids, and clinical trials contributes to refining biological insights and unraveling subtype‐specific therapies in CRC. Therapeutic interventions including nanotechnology, clustered regulatory interspaced short palindromic repeat/CRISPR‐associated nuclease 9 (CRISPR/Cas9), gut microbiome, and liquid biopsy are powerful tools with the possibility to shift the immunologic landscape and outlook for CRC precise medicine.

oncology
Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer

Jonas Langerud,Ina A Eilertsen,Seyed H Moosavi,Solveig M K Klokkerud,Henrik M Reims,Ingeborg F Backe,Merete Hektoen,Ole H Sjo,Marine Jeanmougin,Sabine Tejpar,Arild Nesbakken,Ragnhild A Lothe,Anita Sveen

DOI: https://doi.org/10.1038/s41467-024-48706-2

2024-05-21

Abstract:Intra-tumor heterogeneity compromises the clinical value of transcriptomic classifications of colorectal cancer. We investigated the prognostic effect of transcriptomic heterogeneity and the potential for classifications less vulnerable to heterogeneity in a single-hospital series of 1093 tumor samples from 692 patients, including multiregional samples from 98 primary tumors and 35 primary-metastasis sets. We show that intra-tumor heterogeneity of the consensus molecular subtypes (CMS) is frequent and has poor-prognostic associations independently of tumor microenvironment markers. Multiregional transcriptomics uncover cancer cell-intrinsic and low-heterogeneity signals that recapitulate the intrinsic CMSs proposed by single-cell sequencing. Further subclassification identifies congruent CMSs that explain a larger proportion of variation in patient survival than intra-tumor heterogeneity. Plasticity is indicated by discordant intrinsic phenotypes of matched primary and metastatic tumors. We conclude that multiregional sampling reconciles the prognostic power of tumor classifications from single-cell and bulk transcriptomics in the context of intra-tumor heterogeneity, and phenotypic plasticity challenges the reconciliation of primary and metastatic subtypes.
Generalizable transcriptome-based tumor malignant level evaluation and molecular subtyping towards precision oncology

Dingxue Hu,Ziteng Zhang,Xiaoyi Liu,Youchun Wu,Yunyun An,Wanqiu Wang,Mengqi Yang,Yuqi Pan,Kun Qiao,Changzheng Du,Yu Zhao,Yan Li,Jianqiang Bao,Tao Qin,Yue Pan,Zhaohua Xia,Xin Zhao,Kun Sun

DOI: https://doi.org/10.1186/s12967-024-05326-0

IF: 8.44

2024-05-30

Journal of Translational Medicine

Abstract:In cancer treatment, therapeutic strategies that integrate tumor-specific characteristics (i.e., precision oncology) are widely implemented to provide clinical benefits for cancer patients. Here, through in-depth integration of tumor transcriptome and patients' prognoses across cancers, we investigated dysregulated and prognosis-associated genes and catalogued such important genes in a cancer type-dependent manner. Utilizing the expression matrices of these genes, we built models to quantitatively evaluate the malignant levels of tumors across cancers, which could add value to the clinical staging system for improved prediction of patients' survival. Furthermore, we performed a transcriptome-based molecular subtyping on hepatocellular carcinoma, which revealed three subtypes with significantly diversified clinical outcomes, mutation landscapes, immune microenvironment, and dysregulated pathways. As tumor transcriptome was commonly profiled in clinical practice with low experimental complexity and cost, this work proposed easy-to-perform approaches for practical clinical promotion towards better healthcare and precision oncology of cancer patients.

medicine, research & experimental
Subtype-MGTP: a cancer subtype identification framework based on multi-omics translation

Minzhu Xie,Yabin Kuang,Mengyun Song,Ergude Bao

DOI: https://doi.org/10.1093/bioinformatics/btae360

IF: 5.8

2024-06-01

Bioinformatics

Abstract:Abstract Motivation The identification of cancer subtypes plays a crucial role in cancer research and treatment. With the rapid development of high-throughput sequencing technologies, there has been an exponential accumulation of cancer multi-omics data. Integrating multi-omics data has emerged as a cost-effective and efficient strategy for cancer subtyping. While current methods primarily rely on genomics data, protein expression data offers a closer representation of phenotype. Therefore, integrating protein expression data holds promise for enhancing subtyping accuracy. However, the scarcity of protein expression data compared to genomics data presents a challenge in its direct incorporation into existing methods. Moreover, striking a balance between omics-specific learning and cross-omics learning remains a prevalent challenge in current multi-omics integration methods. Results We introduce Subtype-MGTP, a novel cancer subtyping framework based on the translation of Multiple Genomics To Proteomics. Subtype-MGTP comprises two modules: a translation module, which leverages available protein data to translate multi-type genomics data into predicted protein expression data, and an improved deep subspace clustering module, which integrates contrastive learning to cluster the predicted protein data, yielding refined subtyping results. Extensive experiments conducted on benchmark datasets demonstrate that Subtype-MGTP outperforms nine state-of-the-art cancer subtyping methods. The interpretability of clustering results is further supported by the clinical and survival analysis. Subtype-MGTP also exhibits strong robustness against varying rates of missing protein data and demonstrates distinct advantages in integrating multi-omics data with imbalanced multi-omics data. Availability and implementation The code and results are available at https://github.com/kybinn/Subtype-MGTP.

biochemical research methods,biotechnology & applied microbiology,mathematical & computational biology
Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

Laetitia Marisa,Aurélien de Reyniès,Alex Duval,Janick Selves,Marie Pierre Gaub,Laure Vescovo,Marie-Christine Etienne-Grimaldi,Renaud Schiappa,Dominique Guenot,Mira Ayadi,Sylvain Kirzin,Maurice Chazal,Jean-François Fléjou,Daniel Benchimol,Anne Berger,Arnaud Lagarde,Erwan Pencreach,Françoise Piard,Dominique Elias,Yann Parc,Sylviane Olschwang,Gérard Milano,Pierre Laurent-Puig,Valérie Boige

DOI: https://doi.org/10.1371/journal.pmed.1001453

2013-05-21

PLoS Medicine

Abstract:BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses.METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available.CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.

medicine, general & internal
Identifying gastric cancer molecular subtypes by integrating DNA-based hierarchical classification strategy and clinical stratification

Binyu Yang,Siying Liu,Jiemin Xie,Xi Tang,Pan Guan,Yifan Zhu,Li C. Xia

DOI: https://doi.org/10.1101/2023.06.09.544302

2023-06-11

Abstract:Abstract Background Molecular subtyping has been introduced to better understand the genetic landscape of gastric cancer ( GC ), but current subtyping methods only had limited success because of the mixed use of molecular features, a lack of strategy optimization, and the limited availability of GC samples. The community urgently calls for a precise, and easily adoptable subtyping method to enable DNA-based early screening and treatment. Methods Based on TCGA subtypes, we developed a novel classifier, termed Hierarchical DNA-based Classifier for Gastric Cancer Molecular Subtyping ( HCG ), leveraging all DNA-level alterations as predictors, including gene mutations, copy number aberrations and methylations. By adding the closely related esophageal adenocarcinomas ( EA ) dataset, we expanded the TCGA GC dataset for training and testing HCG (n=453). We optimized HCG with three hierarchical strategies evaluated by their overall accuracy using Lasso-Logistic regression, and by their clinical stratification capacity using multivariate survival analysis. We used difference tests to identify subtype-specific DNA alteration biomarkers based on HCG defined subtypes. Results Our HCG classifier achieved an overall AUC score of 0.95 and significantly improved the clinical stratification of patients (overall p-value=0.032). 25 subtype-specific DNA alterations were identified by difference tests, including high level of mutations in SYNE1 , ITGB4 and COL22A1 genes for the MSI subtype, high level of methylations of ALS2CL , KIAA0406 and RPRD1B genes for the EBV subtype. Conclusions HCG is an accurate and robust classifier for DNA-based GC molecular subtyping with high-performing clinical stratification capacity. The training and test datasets and analysis programs of HCG are available at https://github.com/labxscut/HCG .
Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses

Jeppe F. Severens,E. Onur Karakaslar,Bert A. van der Reijden,Elena Sánchez-López,Redmar R. van den Berg,Constantijn J. M. Halkes,Peter van Balen,Hendrik Veelken,Marcel J. T. Reinders,Marieke Griffioen,Erik B. van den Akker

DOI: https://doi.org/10.1038/s41375-024-02137-6

2024-02-16

Leukemia

Abstract:Subtyping of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic abnormalities, but recent literature indicates that transcriptomic phenotyping holds immense potential to further refine AML classification. Here we integrated five AML transcriptomic datasets with corresponding genetic information to provide an overview ( n = 1224) of the transcriptomic AML landscape. Consensus clustering identified 17 robust patient clusters which improved identification of CEBPA -mutated patients with favourable outcomes, and uncovered transcriptomic subtypes for KMT2A rearrangements (2), NPM1 mutations (5), and AML with myelodysplasia-related changes (AML-MRC) (5). Transcriptomic subtypes of KMT2A , NPM1 and AML-MRC showed distinct mutational profiles, cell type differentiation arrests and immune properties, suggesting differences in underlying disease biology. Moreover, our transcriptomic clusters show differences in ex-vivo drug responses, even when corrected for differentiation arrest and superiorly capture differences in drug response compared to genetic classification. In conclusion, our findings underscore the importance of transcriptomics in AML subtyping and offer a basis for future research and personalised treatment strategies. Our transcriptomic compendium is publicly available and we supply an R package to project clusters to new transcriptomic studies.

oncology,hematology
Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering

Xianyu Hu,Zhenglin Wang,Qing Wang,Ke Chen,Qijun Han,Suwen Bai,Juan Du,Wei Chen

DOI: https://doi.org/10.1016/j.biopha.2021.112222

2021-12-01

Abstract:BackgroundGlobally, gastric cancer (GC) is the fifth most common tumor. It is necessary to identify novel molecular subtypes to guide patient selection for specific target therapeutic benefits.MethodsMulti-omics data, including transcriptomics RNA-sequencing (mRNA, LncRNA, miRNA), DNA methylation, and gene mutations in the TCGA-STAD cohort were used for the clustering. Ten classical clustering algorithms were executed to recognize patients with different molecular features using the "MOVICS" package in R. The activated signaling pathways were evaluated using the single-sample gene set enrichment analysis. The differential distribution of gene mutations, copy number alterations, and tumor mutation burden was compared, and potential responses to immunotherapy and chemotherapy were also assessed.ResultsTwo molecular subtypes (CS1 and CS2) were recognized by ten clustering algorithms with consensus ensembles. Patients in the CS1 group had a shorter average overall survival time (28.5 vs. 68.9 months, P = 0.016), and progression-free survival (19.0 vs. 63.9 months, P = 0.008) as compared to those in the CS2 group. Extracellular associated biological process activation was higher in the CS1 group, while the CS2 group displayed the enhanced activation of cell cycle-associated pathways. Significantly higher total mutation numbers and neoantigens were observed in the CS2 group, along with specific mutations in TTN, MUC16, and ARID1A. Higher infiltration of immunocytes was also observed in the CS2 group, reflective of the potential immunotherapeutic benefits. Moreover, the CS2 group could also respond to 5-fluorouracil, cisplatin, and paclitaxel. The similar diversity in clinical outcomes between CS1 and CS2 groups was successfully validated in the external cohorts, GSE62254, GSE26253, GSE15459, and GSE84437.ConclusionThe findings provided novel insights into the GC subtypes through integrative analysis of five -omics data by ten clustering algorithms. These could provide potential clinical therapeutic targets based on the specific molecular features.

pharmacology & pharmacy,medicine, research & experimental
[Modifications by 4 amino-pyridine of electric characteristics of the isolated giant axon of an insect, the cockroach (Periplaneta americana L.)].

M. Pelhate,B. Hue,J. Chanelet

Abstract:
Clustering of Transcriptomic Data for the Identification of Cancer Subtypes

Xiaochun Chen,Honggang Wang,Donghui Yan

DOI: https://doi.org/10.48550/arXiv.1811.09926

2018-11-25

Applications

Abstract:Cancer is a number of related yet highly heterogeneous diseases. Correct identification of cancer subtypes is critical for clinical decisions. The advance in sequencing technologies has made it possible to study cancer based on abundant genomics and transcriptomic (-omics) data. Such a data-driven approach is expected to address limitations and issues with traditional methods in identifying cancer subtypes. We evaluate the suitability of clustering--a data mining tool to study heterogenous data when there is a lack of sufficient understanding of the subject matters--in the identification of cancer subtypes. A number of popular clustering algorithms and their consensus are explored, and we find cancer subtypes identified by consensus clustering agree well with clinical studies.
Molecular and cellular heterogeneity of gastric cancer explained by methylation-driven key regulators

Seungyeul Yoo,Quan Chen,Li Wang,Wenhui Wang,Ankur Chakravarthy,Rita Busuttil,Alex Boussioutas,Dan Liu,Junjun She,Tim R. Fenton,Jiangwen Zhang,Xiaodan Fan,Suet-Yi Leung,Jun Zhu

DOI: https://doi.org/10.1101/2020.01.27.920744

IF: 10.1

2020-01-01

Cancer Immunology Research

Abstract:Gastric cancer (GC) is a heterogeneous disease of diverse genetic, genomic, and epigenetic alterations. Tumor microenvironment (TME) also contributes to the heterogeneity of GC. To investigate GC heterogeneity, we developed an Integrative Sequential Causality Test (ISCT) to identify key regulators of GC by integrating DNA methylation, copy number variation, and transcriptomic data. Applying ISCT to three GC cohorts containing methylation, CNV and transcriptomic data, 11 common methylation-driven key regulators () were identified. Based on these 11 genes, gastric tumors were clustered into 3 clusters which were associated with known molecular subtypes, Lauren classification, tumor stage, and patient survival, suggesting significance of the methylation-driven key regulators in molecular and histological heterogeneity of GC. We further showed that chemotherapy benefit was different in the 3 GC clusters and varied depending on the tumor stage. Both immune/stromal proportions in TME and tumor cell genomic variations contributed to expression variations of the 11 methylation-driven key regulators and to the GC heterogeneity.
Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in gastric cancer

Guoqiang Tao,Xiangyu Wen,Xingxing Wang,Qi Zhou

DOI: https://doi.org/10.1038/s41598-023-35395-y

IF: 4.6

2023-05-31

Scientific Reports

Abstract:Abstract Metabolic reprogramming has been defined as a key hall mark of human tumors. However, metabolic heterogeneity in gastric cancer has not been elucidated. Here we separated the TCGA-STAD dataset into two metabolic subtypes. The differences between subtypes were elaborated in terms of transcriptomics, genomics, tumor-infiltrating cells, and single-cell resolution. We found that metabolic subtype 1 is predominantly characterized by low metabolism, high immune cell infiltration. Subtype 2 is mainly characterized by high metabolism and low immune cell infiltration. From single-cell resolution, we found that the high metabolism of subtype 2 is dominated by epithelial cells. Not only epithelial cells, but also various immune cells and stromal cells showed high metabolism in subtype 2 and low metabolism in subtype 1. Our study established a classification of gastric cancer metabolic subtypes and explored the differences between subtypes from multiple dimensions, especially the single-cell resolution.

multidisciplinary sciences
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Zhengdeng Lei,Iain Beehuat Tan,Kakoli Das,Niantao Deng,Hermioni Zouridis,Sharon Pattison,Clarinda Chua,Zhu Feng,Yeoh Khay Guan,Chia Huey Ooi,Tatiana Ivanova,Shenli Zhang,Minghui Lee,Jeanie Wu,Anna Ngo,Sravanthy Manesh,Elisabeth Tan,Bin Tean Teh,Jimmy Bok Yan So,Liang Kee Goh,Alex Boussioutas,Tony Kiat Hon Lim,Horst Flotow,Patrick Tan,Steven G Rozen

DOI: https://doi.org/10.1053/j.gastro.2013.05.010

IF: 29.4

2013-01-01

Gastroenterology

Abstract:Almost all gastric cancers are adenocarcinomas, which have considerable heterogeneity among patients. We sought to identify subtypes of gastric adenocarcinomas with particular biological properties and responses to chemotherapy and targeted agents.We compared gene expression patterns among 248 gastric tumors; using a robust method of unsupervised clustering, consensus hierarchical clustering with iterative feature selection, we identified 3 major subtypes. We developed a classifier for these subtypes and validated it in 70 tumors from a different population. We identified distinct genomic and epigenomic properties of the subtypes. We determined drug sensitivities of the subtypes in primary tumors using clinical survival data, and in cell lines through high-throughput drug screening.We identified 3 subtypes of gastric adenocarcinoma: proliferative, metabolic, and mesenchymal. Tumors of the proliferative subtype had high levels of genomic instability, TP53 mutations, and DNA hypomethylation. Cancer cells of the metabolic subtype were more sensitive to 5-fluorouracil than the other subtypes. Furthermore, in 2 independent groups of patients, those with tumors of the metabolic subtype appeared to have greater benefits with 5-fluorouracil treatment. Tumors of the mesenchymal subtype contain cells with features of cancer stem cells, and cell lines of this subtype are particularly sensitive to phosphatidylinositol 3-kinase-AKT-mTOR inhibitors in vitro.Based on gene expression patterns, we classified gastric cancers into 3 subtypes, and validated these in an independent set of tumors. The subgroups have differences in molecular and genetic features and response to therapy; this information might be used to select specific treatment approaches for patients with gastric cancer.
Transcriptome Based System Biology Exploration Reveals Homogeneous Tumorigenicity of Alimentary Tract Malignancy

Yu-Chen Lu,Jing-Qi Shi,Zi-Xin Zhang,Jia-Yi Zhou,Hai-Kun Zhou,Yuan-Cai Feng,Zhen-Hua Lu,Shu-Ya Yang,Xi-Yang Zhang,Yang Liu,Zi-Chao Li,Yuan-Jie Sun,Lian-He Zheng,Dong-Bo Jiang,Kun Yang

DOI: https://doi.org/10.3389/fonc.2020.580276

IF: 4.7

2021-01-22

Frontiers in Oncology

Abstract:Malignancies of alimentary tract include esophageal carcinoma (ESCA), stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD), and rectum adenocarcinoma (READ). Despite of their similarities in cancer development and progression, there are numerous researches concentrating on single tumor but relatively little on their common mechanisms. Our study explored the transcriptomic data of digestive tract cancers from The Cancer Genome Atlas database, yielding their common differentially expressed genes including 1,700 mRNAs, 29 miRNAs, and 362 long non-coding RNAs (lncRNAs). There were 12 mRNAs, 5 miRNAs, and 16 lncRNAs in the core competitive endogenous RNAs network by RNA-RNA interactions, highlighting the prognostic nodes of SERPINE1, hsa-mir-145, and SNHG1. In addition, the weighted gene co-expression network analysis (WGCNA) illustrated 20 gene modules associated with clinical traits. By taking intersections of modules related to the same trait, we got 67 common genes shared by ESCA and READ and screened 5 hub genes, including ADCY6, CXCL3, NPBWR1, TAS2R38, and PTGDR2. In conclusion, the present study found that SERPINE1/has-mir-145/SNHG1 axis acted as promising targets and the hub genes reasoned the similarity between ESCA and READ, which revealed the homogeneous tumorigenicity of digestive tract cancers at the transcriptome level and led to further comprehension and therapeutics for digestive tract cancers.

oncology
Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor microenvironment and metabolic interplay

XianTao Lin,Ping Yang,MingKun Wang,Xiuting Huang,Baiyao Wang,Chengcong Chen,Anan Xu,Jiazuo Cai,Muhammad Khan,Sha Liu,Jie Lin

DOI: https://doi.org/10.3389/fphar.2024.1355269

IF: 5.6

2024-06-20

Frontiers in Pharmacology

Abstract:Gastric cancer, the fifth most prevalent cancer worldwide, is often diagnosed in advanced stages with limited treatment options. Examining the tumor microenvironment (TME) and its metabolic reprogramming can provide insights for better diagnosis and treatment. This study investigates the link between TME factors and metabolic activity in gastric cancer using bulk and single-cell RNA-sequencing data. We identified two molecular subtypes in gastric cancer by analyzing the distinct expression patterns of 81 prognostic genes related to the TME and metabolism, which exhibited significant protein-level interactions. The high-risk subtype had increased stromal content, fibroblast and M2 macrophage infiltration, elevated glycosaminoglycans/glycosphingolipids biosynthesis, and fat metabolism, along with advanced clinicopathological features. It also exhibited low mutation rates and microsatellite instability, associating it with the mesenchymal phenotype. In contrast, the low-risk group showed higher tumor content and upregulated protein and sugar metabolism. We identified a 15-gene prognostic signature representing these characteristics, including CPVL, KYNU, CD36, and GPX3, strongly correlated with M2 macrophages, validated through single-cell analysis and an internal cohort. Despite resistance to immunotherapy, the high-risk group showed sensitivity to molecular targeted agents directed at IGF-1R (BMS-754807) and the PI3K-mTOR pathways (AZD8186, AZD8055). We experimentally validated these promising drugs for their inhibitory effects on MKN45 and MKN28 gastric cells. This study unveils the intricate interplay between TME and metabolic pathways in gastric cancer, offering potential for enhanced diagnosis, patient stratification, and personalized treatment. Understanding molecular features in each subtype enriches our comprehension of gastric cancer heterogeneity and potential therapeutic targets.

pharmacology & pharmacy
Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses

Fangjie Hu,Jianyi Wang,Minghui Zhang,Shuoshuo Wang,Lingyu Zhao,Hao Yang,Jinrong Wu,Binbin Cui

DOI: https://doi.org/10.3389/fcell.2021.758776

IF: 5.5

2021-01-01

Frontiers in Cell and Developmental Biology

Abstract:Colon cancer is a complex, heterogeneous disease. The Colorectal Cancer Subtyping Consortium reported a novel classification system for colon cancer in 2015 to better understand its heterogeneity. This molecular classification system divided colon cancer into four distinct consensus molecular subtypes (CMS 1, 2, 3, and 4). However, the characteristics of different colon cancer molecular subtypes have not been fully elucidated. This study comprehensively analyzed the molecular characteristics of varying colon cancer subtypes using multiple databases and algorithms, including The Cancer Genome Atlas (TCGA) database, DriverDBv3 database, CIBERSORT, and MCP-counter algorithms. We analyzed the alterations in the subtype-specific genes of different colon cancer subtypes, such as the RNA levels and DNA alterations, and showed that specific subtype-specific genes significantly affected prognosis. We also explored the changes in colon cancer driver genes and representative genes of 10 signaling pathways in different subtypes. We identified genes that were altered in specific subtypes. We further detected the infiltration of 22 immune cell types in four colon cancer subtypes and the infiltration level of primary immune cells among these subtypes. Additionally, we explored changes in immune checkpoint genes (ICGs) and immunotherapy responses among different colon cancer subtypes. This study may provide clues for the molecular mechanism of tumorigenesis and progression in colon cancer. It also offers potential biomarkers and targets for the clinical diagnosis and treatment of different colon cancer subtypes.

Crystal structure of rhizavidin: insights into the enigmatic high-affinity interaction of an innate biotin-binding protein dimer.

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity

Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics

The Combination of Exon Sequencing and Metabolomics to Establish a Molecular Typing System for Gastric Cancer

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer

Generalizable transcriptome-based tumor malignant level evaluation and molecular subtyping towards precision oncology

Subtype-MGTP: a cancer subtype identification framework based on multi-omics translation

Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

Identifying gastric cancer molecular subtypes by integrating DNA-based hierarchical classification strategy and clinical stratification

Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses

Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering

[Modifications by 4 amino-pyridine of electric characteristics of the isolated giant axon of an insect, the cockroach (Periplaneta americana L.)].

Clustering of Transcriptomic Data for the Identification of Cancer Subtypes

Molecular and cellular heterogeneity of gastric cancer explained by methylation-driven key regulators

Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in gastric cancer

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Transcriptome Based System Biology Exploration Reveals Homogeneous Tumorigenicity of Alimentary Tract Malignancy

Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor microenvironment and metabolic interplay

Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses